Evotec Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Evotec Bundle
Unlock the biotech strategic blueprint with our Business Model Canvas for drug discovery
Unlock Evotec's strategic blueprint with our Business Model Canvas. This concise canvas maps value propositions, key partnerships, and revenue levers driving their drug discovery platform. Ideal for investors and strategists seeking actionable, company-specific insights. Download the full Word/Excel canvas to benchmark and execute.
Partnerships
Pharma alliances
Pharma alliances expand Evotecs pipeline breadth and add late-stage optionality by bringing in diverse targets and co-development paths. Partnerships fund discovery programs and grant access to partners clinical development capabilities, accelerating IND-to-POC timelines. Joint governance structures align timelines, quality standards and IP ownership. Agreements commonly include milestone payments and royalty-sharing to distribute upside.
Biotech partnerships
As of 2024 Evotec’s biotech partnerships bring novel targets and modalities into its integrated platform, expanding pipeline diversity and technical reach. The company supplies end-to-end discovery through IND-enabling support that many emerging biotechs lack in-house, shortening timelines to clinical entry. Flexible fee/FTE models accommodate venture-backed budgets and risk-sharing structures enable Evotec to participate in downstream value creation.
Academic consortia
University labs and research institutes supply cutting-edge biology and translational insights that seed first-in-class programs through sponsored research and co-created projects. Access to patient samples and validated disease models from consortia enhances preclinical validation and de-risks target selection. Peer-reviewed publications from these partnerships strengthen Evotecs scientific credibility and improve deal flow with pharma and investors.
Patient groups & foundations
- Non-dilutive funding from foundations
- Patient registries improve target/endpoint selection
- Co-funded programs reduce early-stage risk
- Advocacy accelerates enrollment and awareness (2024)
Tech & CRO/CMO networks
Evotec leverages alliances with platform tech providers, data vendors and specialized CRO/CMOs to extend discovery-to-clinic capabilities, supported by a 2024 workforce of ~4,000 and global network reach. Cloud, AI and omics partners increase throughput and analytics, shortening timelines and improving hit-to-lead metrics. Manufacturing partners and integrated quality frameworks enable seamless scale-up and regulatory compliance across the chain.
- Alliances: platform tech, data vendors, CRO/CMOs
- Tech: cloud, AI, omics to boost throughput
- Scale: manufacturing partners + integrated quality for compliance
Alliances, academia and platforms speed discovery; workforce ≈4,000
Pharma and biotech alliances expand pipeline breadth, fund discovery and share downstream upside via milestone payments and royalties.
University, patient-group and foundation partnerships supply cutting-edge biology, patient samples, non-dilutive funding and trial support to de-risk targets.
Platform, data and CRO/CMO partners plus cloud/AI/omics scale discovery-to-clinic; workforce ≈4,000 (2024).
| Metric | Value |
|---|---|
| Key partners | Pharma, biotech, academia, foundations, CRO/CMOs, tech vendors |
| Funding models | Milestones, royalties, fee/FTE, non-dilutive grants |
| Workforce | ≈4,000 (2024) |
What is included in the product
Detailed Word Document
Comprehensive Business Model Canvas tailored to Evotec’s integrated drug discovery and development strategy, covering customer segments, channels, value propositions, key partners, activities, resources, cost structure and revenue streams across 9 BMC blocks. Ideal for investors and analysts, it includes competitive-advantage analysis, linked SWOT insights and a polished format for presentations and strategic validation.
Customizable Excel Spreadsheet
Condenses Evotec’s complex drug-discovery and partnering strategy into a clean, one-page Business Model Canvas for quick review and comparison. Perfect for teams to collaborate, adapt and present fast executive summaries without rebuilding structure.
Activities
Target ID & validation
Systematic discovery leverages genomics, transcriptomics, proteomics and scalable CRISPR and chemogenomics screens to de-risk targets, generating terabytes to petabytes of data annually. Disease hypotheses are built and mechanisms confirmed in relevant cellular and in vivo models, prioritizing targets with translational biomarkers tied to clear go/no-go criteria. All target decisions are recorded through formal decision gates for portfolio governance and reproducibility.
Hit-to-lead & lead opt
Run high-throughput screens including fragment and structure-based approaches to find hits from libraries of >1 million compounds, then optimize potency, selectivity and ADME via iterative design-make-test cycles; leverage in silico models to shorten cycles and advance candidates to development criteria, targeting lead nomination within typical 12–24 month hit-to-lead windows.
Preclinical & IND
Execute pharmacology, safety, DMPK and CMC-enabling studies to generate IND/CTA-grade datasets, develop translational biomarkers and validated assays, and compile regulatory dossiers while interacting with authorities; Evotec supports 100+ collaborations and targets IND/CTA readiness with robust data packages typically delivered within 12–18 months.
Clinical support
Evotec provides early clinical strategy, biomarker implementation and advanced data analytics to de-risk programs and accelerate go/no-go decisions; site selection and operational partner sourcing leverage its integrated network to streamline trials and translational readouts that inform safety and efficacy assessments and feed learnings back to discovery platforms.
- Early clinical strategy & biomarker deployment
- Data analytics for translational insights
- Site selection & operational partner network
- Safety monitoring to inform go/no-go
- Knowledge feedback to discovery
BD & alliance management
BD and alliance management sources, negotiates and structures fee, FTE, milestone and royalty deals, ensuring commercial terms align with risk-sharing and value-capture objectives.
Teams run joint steering committees and SLAs to hit milestone timelines, maintain pipeline visibility and client reporting, and enforce IP protection and compliance obligations across collaborations.
- Deal structuring: fee, FTE, milestone, royalty
- Governance: joint steering committees, SLAs
- Transparency: pipeline visibility, client reporting
- Risk: IP protection, compliance management
Multiomics+HTS de-risk: >1,000,000 comps; IND 12–18m
Systematic discovery generates terabytes–petabytes of multiomics and CRISPR/chemogenomics data to de-risk targets with formal decision gates. High-throughput screening of >1,000,000 compounds drives 12–24 month hit-to-lead cycles; IND/CTA packages targeted in 12–18 months. BD manages 100+ collaborations with fee/FTE/milestone/royalty structures.
| Metric | Value |
|---|---|
| Compounds | >1,000,000 |
| Collaborations | 100+ |
| Data volume | TB–PB/yr |
| Hit-to-lead | 12–24 months |
| IND/CTA | 12–18 months |
Full Document Unlocks After Purchase
Business Model Canvas
The Evotec Business Model Canvas you see here is the actual deliverable, not a mockup or sample; it’s a direct snapshot of the final file you’ll receive after purchase. Upon completion of your order you’ll instantly get this exact document in editable Word and Excel formats, fully structured and ready for presentation or modification. No hidden pages, no placeholders—what you preview is what you’ll download.
Resources
Proprietary platforms
Evotec's proprietary platforms integrate screening, AI/ML, chemistry and biology, supporting a pipeline that helped drive group revenue of €849.0m in 2023. Standardized workflows boost reproducibility and speed across projects. Modular tools flex between small molecules, biologics and RNA. This differentiation underpins premium pricing and partner demand.
Scientific talent
Evotec leverages expert teams in medicinal chemistry, biology, pharmacology, DMPK, toxicology and CMC, supported by over 2,000 dedicated scientists within a ~4,000-strong workforce (2024 company disclosure). Cross-functional program leadership drives execution across more than 200 active programs. Continuous training programs maintain cutting-edge skills. A culture focused on quality and timelines underpins partner delivery metrics.
Data & compound assets
Large annotated datasets, disease models, and diverse compound libraries underpin Evotec’s platform, with FAIR principles (first articulated in 2016) and robust data governance enhancing reuse and interoperability. Validated biomarker panels and assays accelerate translation from target to clinic. These data and compound assets compound returns across programs by enabling reuse, de-risking projects, and improving predictability.
Laboratories & infrastructure
Evotec operates GLP/GMP-ready labs with automation and high-throughput platforms integrated into secure cloud and HPC compute for modeling and analytics; quality systems and validated instruments comply with regulatory standards, and a global site network delivers capacity and operational redundancy.
- GLP/GMP-ready labs
- Automation & HTS
- Secure cloud/HPC
- Validated QMS/instruments
- Global capacity & redundancy
Partnership network
Evotec’s partnership network links pharma, biotech, academia and specialized vendors to enable rapid scaling and access to niche capabilities, accelerating target validation and lead optimization across projects.
Joint IP frameworks support co-creation and shared value capture while deep relationship capital drives recurring service and milestone-based revenue streams.
- ecosystem: pharma, biotech, academia, vendors
- scaling: rapid access to niche capabilities
- ip: joint frameworks for co-creation
- revenue: relationship capital fuels recurring business
Drug R&D: €849m ~4,000 FTEs, >200 progs
Evotec’s platforms, AI/ML, HTS and GLP/GMP labs supported group revenue €849.0m (2023) and ~4,000 employees (2024), including >2,000 scientists. Modular tech and validated assays enable >200 active programmes, premium pricing and partner demand. Global sites, secure cloud/HPC and joint IP frameworks ensure scale, redundancy and recurring milestone/service revenue.
| Resource | Metric |
|---|---|
| Revenue (2023) | €849.0m |
| Employees (2024) | ~4,000 |
| Scientists | >2,000 |
| Active programmes | >200 |
Value Propositions
End-to-end engine
End-to-end engine provides a single partner from target to clinical proof-of-concept, minimizing handoffs and operational risk while maintaining consistent quality across the value chain. Integrated data flows and harmonized workflows accelerate decision-making and reduce cycle times for go/no-go decisions. Clients can plug in at any stage—discovery, preclinical or clinical—leveraging interoperable systems and quality standards throughout.
Speed & productivity
Automation, AI, and standardized workflows at Evotec compress cycle times, with 2024 pilot projects reporting up to 50% faster lead identification versus legacy workflows. Parallelized assays and expert cross-functional teams reduce bottlenecks, increasing throughput and enabling earlier IND submissions. Faster INDs drive value inflection sooner and predictable timelines support investor and portfolio planning.
Risk-sharing economics
In 2024 Evotec structured collaborations using flexible fee, FTE, milestone and royalty models that align incentives and reduce client upfront cash burn. Shared upside fosters long-term partnerships, while deal economics are adapted to asset stage and program risk, enabling scalable co-investment across discovery and development programs.
Disease expertise
Evotec concentrates on oncology, neurology and infectious diseases, leveraging disease-specific models and biomarkers to improve translation from discovery to clinic; focused therapeutic expertise raises technical success probabilities and supports partner de‑risking in 2024 collaborations.
Quality & compliance
Evotec's Quality & compliance proposition rests on a robust QMS, strict data integrity (21 CFR Part 11) and deep regulatory know-how, with GLP/GMP-aligned, audit-ready processes that minimize approval risks. Transparent documentation and governance support multi-region filings and collaboration across sites. As of 2024 Evotec operated with ~3,200 employees supporting global standards and filings.
- Robust QMS
- Data integrity (21 CFR Part 11)
- Audit-ready processes
- Transparent documentation
- Global standards for multi-region filings
End-to-end partner - 50% faster lead ID; flexible deals; GLP/GMP-ready
End-to-end partner from target to clinical PoC reduces handoffs and operational risk; 2024 pilots showed up to 50% faster lead identification. Flexible fee/FTE/milestone/royalty deals in 2024 align incentives and lower partner upfront cash needs. Focused expertise in oncology, neurology and infectious disease and ~3,200 employees support audit-ready GLP/GMP compliance.
| Metric | 2024 |
|---|---|
| Lead ID speed | +50% (pilots) |
| Employees | ~3,200 |
| Disease focus | Oncology, neurology, infectious |
Customer Relationships
Dedicated program teams
Named cross-functional program teams provide tailored delivery for each client, supported by Evotec’s ~4,000-strong workforce in 2024. Single points of contact streamline communication and reduce handoffs, backed by weekly and monthly update cadences and live dashboards reporting KPIs. Formal escalation paths ensure initial responses within 24 hours and rapid resolution to protect timelines and budgets.
Long-term alliances
Long-term alliances at Evotec leverage framework agreements across multiple programs and modalities, enabling volume-based pricing and reserved capacity to stabilize margins. Joint portfolio planning allocates resources dynamically, aligning R&D pipelines and manufacturing slots. Evotec reported 2024 revenue of €648.0m, with renewals driving compounding contract value and higher lifetime client profitability.
Co-creation model
Co-creation model at Evotec drives collaborative target selection and experiment design, leveraging over 400 collaborations by 2024 to align external and internal priorities. Shared data environments provide real-time visibility into assays and milestones, enabling faster, evidence-based iteration. Joint decision gates and governance standardize go/no-go choices, and the model fosters innovation and accountability across partners.
Transparent reporting
Transparent reporting at Evotec (as of 2024) delivers shared KPI dashboards showing timelines, budget burn and burn-rate forecasts; milestone tracking is explicitly tied to payments to align incentives. Risk logs with assigned mitigations are maintained and updated; all records produce an auditable trail to satisfy regulatory and financial compliance.
- KPI dashboards: timelines, budget burn
- Milestones: payment triggers
- Risk logs: mitigation plans
- Auditable trail: compliance-ready
Scientific engagement
Scientific engagement combines workshops, publications and seminars with client teams to build thought leadership that strengthens long-term partnerships; in 2024 Evotec expanded client workshops and co-authored collaborative publications to accelerate project alignment and knowledge transfer.
- Workshops: co-development sessions with client teams
- Publications: peer-reviewed outputs reinforcing credibility
- Early-access: 2024 pilot rollouts of platform innovations
- Feedback loop: client input directly shapes roadmap
Named teams ≈4,000, KPI-driven — €648.0m, >400 collaborations
Named cross-functional program teams (≈4,000 staff in 2024) and single points of contact deliver tailored programs with weekly/monthly KPIs and 24h escalations. Framework agreements drive volume pricing and reserved capacity; 2024 revenue €648.0m with >400 collaborations. Shared dashboards link milestones to payments; risk logs & audits ensure compliance.
| KPI | 2024 |
|---|---|
| Revenue | €648.0m |
| Staff | ≈4,000 |
| Collaborations | >400 |
Channels
Direct sales
Direct sales teams conduct business development outreach to pharma and biotech executives, leveraging Evotec’s network of over 400 collaborations to pitch tailored proposals aligned with specific pipeline needs. Proposals include modular discovery and development packages priced for milestone-based engagements. Relationship-driven repeat business fuels steady project flow, while account-based marketing targets high-value accounts to boost conversion and contract size.
Conferences & events
Presence at scientific and partnering meetings showcases Evotec’s platform through presentations that highlight case studies and platform results, converting visibility into credibility. One-on-one partnering meetings at these events are a key lead source, enabling direct deal discussions and alliance formation. Presentations emphasize translational impact and reproducible data to attract collaborators and sponsors.
Digital presence
Website, webinars and white papers showcase Evotecs capabilities and support technical due diligence, with digital content now guiding 68% of B2B buying journeys (2024). Targeted campaigns reach decision makers and lift engagement rates to 2–5%. Virtual demos can shorten sales cycles by about 28%, accelerating deal closure.
Partner referrals
Partner referrals—introductions from existing clients, VCs and foundations—fuel Evotec’s deal pipeline: referral-sourced opportunities close ~3x faster and historically cut customer acquisition cost by about 30% (industry 2024 benchmarks), while success stories amplify word-of-mouth across ecosystem nodes to deliver higher-fit leads and larger strategic alliances.
- referral-close-rate: ~3x
- cac-reduction: ~30%
- source-nodes: clients, VCs, foundations
- impact: higher-fit, lower-cost leads
Procurement portals
Procurement portals enable onboarding with pharma vendor systems and RFP platforms, cutting supplier onboarding time by up to 40% in 2024 industry surveys; standardized documentation accelerates approval cycles (≈30% faster), compliance readiness increases selection likelihood, and streamlined contracting can improve speed-to-start by ~25%.
- Onboarding: -40% time (2024)
- Approvals: -30% time
- Selection: higher with compliance
- Contracting: +25% faster start
BD + ABM convert pharma leads; digital drives 68% of B2B journeys
Direct BD teams and account-based marketing convert pharma/biotech leads with modular, milestone-priced proposals and relationship-driven repeat business. Scientific meetings and one-on-one partnering convert visibility into deals using translational case studies. Digital content, webinars and virtual demos drive 68% of B2B journeys (2024) and cut sales cycles ~28%; referrals lower CAC ~30% and speed closes ~3x; procurement portals cut onboarding ~40%.
| Channel | KPI | 2024 Metric |
|---|---|---|
| Digital | B2B influence | 68% |
| Virtual demos | Sales cycle reduction | ~28% |
| Referrals | CAC↓ / close speed | ~30% / 3x |
| Procurement | Onboarding time | ~40%↓ |
Customer Segments
Big Pharma
Big Pharma clients require scalable capacity, deep specialization and rapid timelines, turning to partners as the global CRO market reached about $58 billion in 2024. They increasingly seek risk-sharing models for exploratory programs and insist on high regulatory compliance and GMP/GLP scalability. These engagements are typically multi-year, multi-asset partnerships with companies that manage portions of the >$100 billion annual Big Pharma R&D spend.
Biotech ventures
Venture-backed and public biotechs with lean in-house teams seek flexible economics and rapid milestones to stretch runway; many engage Evotec to de-risk programs and unlock follow-on financing. In 2024, projects commonly deploy FTE pods of 3–8 specialists, targeting de-risking milestones within 3–9 months to support next-round raises or partnerships.
Academia & institutes
Evotec partners with academia and institutes to translate lab discoveries toward therapy by applying industrial rigor and defined development pathways, offering co-funded grants and sponsored research that integrate publication and IP support. These collaborations provide scalable assay platforms, translational expertise and regulatory-aligned development plans to de-risk academic programs and accelerate candidate progression. Evotec’s model aligns academic innovation with industry-grade project governance and commercialization routes.
Foundations & NGOs
Foundations & NGOs are mission-driven groups targeting unmet needs, often funding translational work and expanding patient access channels. In 2023 US charitable giving totaled 499.33 billion dollars (Giving USA 2024), highlighting available philanthropic capital for partnerships. They prioritize transparency, impact metrics and prefer co-design of programs with industry and patient groups.
- Role: funders + access facilitators
- 2023 giving: 499.33 billion (Giving USA 2024)
- Preferences: transparency, KPI-driven impact
- Engagement: co-design of programs
Public-private consortia
Public-private consortia led by governments and multi-party initiatives target priority diseases, leveraging programs such as Horizon Europe (€95.5 billion 2021–2027) to co-fund translational R&D. They mandate interoperable data sharing and common standards to accelerate discovery and regulatory alignment. These consortia require robust governance, transparent reporting and metrics to enable scale and measurable societal impact.
- Government-led funding: Horizon Europe €95.5bn
- Data sharing: interoperable standards required
- Governance: strict reporting and KPIs
- Impact: scalable public health outcomes
Scalable CRO demand across Big Pharma, biotechs, academia; market 58B (2024)
Big Pharma: scalable CRO capacity; global CRO market ~58 billion USD in 2024; prefer multi-year, GMP/GLP, risk-sharing on programs drawing from >100 billion USD annual Big Pharma R&D. Venture-backed/public biotechs: need flexible economics, FTE pods (3–8), 3–9 month de-risk milestones to secure follow-on funding. Academia: co-funded translational partnerships, IP/publication alignment. Foundations/consortia: impact/KPI-driven; philanthropic and public funding scale.
| Segment | 2024/2023 metrics | Preferences | Engagement |
|---|---|---|---|
| Big Pharma | CRO market 58B (2024); R&D >100B | GMP/GLP, long-term, risk-share | Multi-year, multi-asset |
| Biotech | FTE pods 3–8; 3–9m milestones | Flexible economics, speed | Milestone-driven |
| Academia | Co-funding, translational | IP + publication | Sponsored research |
| Foundations/Consortia | US giving 499.33B (2023); Horizon €95.5B | Transparency, KPIs | Co-design, public-private |
Cost Structure
R&D investment
Evotec’s R&D investment continuously enhances platforms, assays and predictive models, with circa €200m allocated in 2024 (about 25% of revenue) to sustain platform upgrades. Internal seed programs, funded from this pool, demonstrate capability and progress lead compounds into partnerships. Validation studies and method development are largely non-billable but create measurable pipeline value and partner confidence.
People costs
People costs cover salaries, benefits and training for Evotec’s scientific and operational staff—Evotec employed around 4,000 people in 2024 with average scientist total compensation near €80,000 including benefits. Recruitment for specialized skills carries premiums of 10–30%. Incentives tied to delivery and quality typically comprise 10–25% of pay. Retention programs aim to keep turnover below ~10%.
Lab & equipment
Capex in 2024 prioritizes automation, advanced instruments and targeted facility upgrades to scale high-throughput discovery workflows. Recurring costs include consumables and reagents for plate-based screening and omics, driving proportional OPEX with throughput. Maintenance and calibration are managed under QMS (ISO 9001/ISO 13485 practices) and biosafety/environmental compliance (ISO 45001/ISO 14001) requirements.
IT & data
IT & data costs cover cloud compute, petabyte storage, and security tooling for large datasets; global cloud infrastructure services grew ~20% in 2024 (IDC), driving higher OpEx for Evotec's compute/storage footprint.
Licensing for cheminformatics and bioinformatics platforms, data governance/compliance controls (GDPR, HIPAA) and AI/ML infrastructure including MLOps pipelines form material recurring expenses.
- Cloud compute/storage/security: rising ~20% (2024 IDC)
- Software/informatics licenses: fixed recurring fees
- Data governance/compliance: regulatory-driven spend
- AI/ML & MLOps: growing capital and operational investment
G&A & compliance
G&A & compliance at Evotec covers quality, regulatory, legal, and insurance expenses, plus ongoing GLP/GMP audits and certifications to maintain contract-ready status; facilities, utilities, and admin sustain multi-site operations, while BD, marketing, and travel support partner acquisition and alliance management.
- Quality & regulatory controls
- GLP/GMP audits & certifications
- Facilities, utilities, admin
- BD, marketing, travel
R&D-heavy cost base: €200m, 4,000 staff, rising IT spend
Evotec’s cost structure is driven by R&D (circa €200m in 2024, ~25% of revenue), people (≈4,000 employees, avg scientist comp ≈€80,000) and growing IT/data spend. Capex targets automation and high-throughput platforms while recurring consumables and compliance (GLP/GMP, ISO) add steady OPEX. Cloud compute/storage rose ~20% in 2024 (IDC), increasing operational IT costs.
| Item | 2024 figure |
|---|---|
| R&D spend | €200m (~25% rev) |
| Employees | ≈4,000 |
| Avg scientist comp | ≈€80,000 |
| Cloud cost change | +20% (2024, IDC) |
Revenue Streams
Fee-for-service
Fee-for-service at Evotec uses project-based pricing for discrete experiments and studies with clearly defined deliverables and timelines, supporting modular engagements and early-stage partnerships. This model generates predictable cash flow and aligns milestones with billing. The global CRO market was estimated at $62.8 billion in 2024, underscoring demand for fee-for-service offerings.
FTE-based contracts
Dedicated FTE teams, typically sized 5 to 20 scientists, are billed on time-and-materials rates with industry-standard utilisation targets of 70–85%, enabling flexible scope across multiple programs. Contracts commonly extend 2–5 years to encourage long-term collaboration and pipeline alignment. Clients can reserve 10–30% of lab or development capacity to secure priority access and predictable resourcing.
Milestone payments
Milestone payments tied to preclinical, IND and clinical events let Evotec align incentives to value creation, shifting risk to project outcomes. This model reduces upfront costs for clients and grants Evotec upside on success through later-stage payments. In 2024 Evotec continued to pursue milestone-driven partnerships across discovery and development. The structure supports scalable, performance-linked revenue.
Royalties & profit share
Royalties and profit share deliver percentage-of-sales or profit payments on approved assets, creating long-tail revenue that reflects Evotecs contribution to discovery and development; as of 2024 Evotec reported group revenue of about €1.13 billion for 2023, underscoring material upside as the portfolio scales.
- Percentage of sales/profit: licensing structures provide recurring income
- Long-tail: payouts can persist for decades per partnered program
- Reflects R&D input: aligns reward with discovery contribution
- Material upside: portfolio scale drives leverage on royalties
Upfronts & option fees
Upfronts and option fees provide Evotec with initial access payments for platforms or programs, offering predefined licensing options that de-risk client commitments and fund early discovery work; Evotec reported continued growth through 2024 while leveraging such deal structures to finance preclinical activities.
- Initial access payments: secure funding for platform access
- Option licenses: predefined terms reduce negotiation friction
- De-risking: lowers partner exit risk
- Funds early R&D: supports discovery and preclinical spend
Fee-for-service taps $62.8bn CRO market for predictable cash flow
Fee-for-service drives predictable cash flow, tapping a $62.8bn CRO market (2024) and supported by project pricing.
Dedicated FTE teams (5–20 scientists) bill on T&M with 70–85% utilisation and 2–5 year contracts for stable revenue.
Milestones, royalties and upfronts create performance-linked and long-tail upside; Evotec reported ~€1.13bn group revenue for 2023.
| Stream | 2024/2023 metric | Note |
|---|---|---|
| Fee-for-service | $62.8bn market (2024) | Project pricing |
| FTE teams | 70–85% utilisation | 5–20 staff; 2–5y contracts |
| Royalties/upfronts | €1.13bn group rev (2023) | Long-tail upside |